AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorTongji Hospital
About this trial
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.
The main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.
Eligibility criteria
Qualifiers
Aged 18-75 years, regardless of gender.
BCLC stage 0-A, scheduled for curative liver resection.
Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).
Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.
Disqualifiers
Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).
Postoperative pathology confirms non-HCC diagnosis.
Pregnant or lactating women.
History of organ transplantation.
Trial design
Treatments tested in this trial
- Curative liver resection
- Real-world multimodal therapy
Treatment groups
353 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov